Obama Brought Silicon Valley to Washington
By Jenna Wortham,
The New York Times
| 10. 25. 2016
This October, the White House opened its doors to a few thousand people for South by South Lawn, a daylong event described as a “festival of ideas, art and action.” Both the event and its name were a nod to South by Southwest, the annual technology-and-music festival held in Austin, Tex., where Barack and Michelle Obama showed up as surprise keynote speakers earlier this year. The story goes that they were so impressed by their experiences, they decided to host their own microrendition before leaving office. Attendees at the White House version — the types of people who describe themselves in Twitter bios as “creator” or “innovator” — were told to dress casually, in clothes suitable for a picnic. The D.J. Beverly Bond, of Black Girls Rock, blasted Public Enemy’s anthem “Fight the Power” and Parliament’s “Flash Light” across the lawn, which was studded with coffee carts, Lego sculptures and virtual-reality stations. Enormous stages erected for the occasion housed a rotating cast of musical guests and speakers throughout the afternoon. As the sun began to set, volunteers handed out plaid...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...